Stevens Capital Management LP Purchases 8,579 Shares of Zoetis Inc. $ZTS

Stevens Capital Management LP grew its position in Zoetis Inc. (NYSE:ZTS) by 241.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,128 shares of the company’s stock after acquiring an additional 8,579 shares during the period. Stevens Capital Management LP’s holdings in Zoetis were worth $1,775,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ZTS. Isthmus Partners LLC lifted its stake in Zoetis by 1.6% in the 3rd quarter. Isthmus Partners LLC now owns 71,493 shares of the company’s stock valued at $10,461,000 after purchasing an additional 1,093 shares during the last quarter. Raiffeisen Bank International AG increased its position in Zoetis by 6.4% during the third quarter. Raiffeisen Bank International AG now owns 204,311 shares of the company’s stock worth $29,229,000 after buying an additional 12,228 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Zoetis by 9.7% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 6,700 shares of the company’s stock valued at $980,000 after buying an additional 593 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Zoetis by 102.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $293,000 after buying an additional 1,014 shares during the period. Finally, D Orazio & Associates Inc. lifted its position in shares of Zoetis by 24.5% in the third quarter. D Orazio & Associates Inc. now owns 1,637 shares of the company’s stock valued at $240,000 after buying an additional 322 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $128.73 on Friday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market cap of $54.34 billion, a price-to-earnings ratio of 21.38, a P/E/G ratio of 1.94 and a beta of 0.96. The stock’s fifty day moving average price is $125.41 and its two-hundred day moving average price is $134.80. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the firm earned $1.40 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.6%. Zoetis’s payout ratio is currently 35.22%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ZTS. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. UBS Group set a $136.00 price target on Zoetis in a report on Thursday, January 29th. Bank of America upped their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Barclays initiated coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.